What is SERA's current stock price?

SERA (Sera Prognostics, Inc.) is currently trading at $2.15 with a market cap of $82.1M.

What sector is Sera Prognostics, Inc. in?

Sera Prognostics, Inc. (SERA) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.

Is SERA a good stock to buy?

Analysts have a Buy consensus on SERA with a price target of $5.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

SERA Sera Prognostics, Inc.

Healthcare

$2.15+3.86%ClosedMarket Cap: $82.1M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.54

P/S

1386.94

EV/EBITDA

-2.39

DCF Value

$-0.02

FCF Yield

-34.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

-191.2%

Operating Margin

-64235.1%

Net Margin

-56386.0%

ROE

-41.0%

ROA

-34.4%

ROIC

-52.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$14.0K	$-8.4M	$—
Q4 null	$10.0K	$-7.9M	$—
FY null	$81.0K	$-31.9M	$—
Q3 null	$16.0K	$-7.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$5.00

Target (Median)

$5.00

Target Range

$5.00 - $5.00

0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Kearney Paul

SellWed May 06

Harrison Robert Gardner

SellWed May 06

Boniface John J.

SellWed May 06

Lindgardt Zhenyadirector, officer: Chief Executive Officer

SellFri Mar 13

Lindgardt Zhenyadirector, officer: Chief Executive Officer

SellFri Mar 13

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

Exchange

—

Beta

0.93

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Peers